Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod Effect on Small Bowel Flow in IBS-C
NCT00171431Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome with constipation (IBS-C) comparing Tegaserod with Placebo (2 arms). Primary endpoint: Motility and small intestinal flow patterns after meal. Started Nov 2004; status: terminated.
02
Drugs
tegaserod
03
Conditions
irritable bowel syndrome with constipation (IBS-C)
Beyond the preview
Go deeper on NCT00171431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171431.